MDGL Q4 2018 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$25,000

Operating Income

-$14M

Net Income

-$11M

EPS (Diluted)

$-0.75

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$485M

Total Liabilities

$8M

Stockholders' Equity

$477M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$25,000	-$60,000	+58.3%
Operating Income	-$14M	-$9M	-62.2%
Net Income	-$11M	-$8M	-35.9%